WILMINGTON, Del--Zeneca Inc. has received FDA clearance to market
Kadian (morphine sulfate sustained release) capsules, a new single
daily dose sustained-release (SR) morphine formulation, for the
management of moderate to severe chronic pain when treatment with
an opioid analgesic is indicated for more than a few days.
Kadian is the first oral SR morphine in the US that offers the
option of 24-hour pain control with a single dose, the company
The largest controlled clinical study of Kadian was conducted
in cancer patients with moderate to severe chronic pain at 28
After stabilization with an immediate-release morphine solution,
152 patients were randomized to receive one of three treatments:
Kadian once every 24 hours, Kadian every 12 hours, or MS Contin
(morphine sulfate controlled-release) every 12 hours.
Kadian once every 24 hours was shown to be as effective as the
other two regimens, and there were no significant differences
in side effects.